Publications by authors named "Francisco Martin-Dominguez"
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Bone Marrow Transplant
December 2024
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD.
View Article and Find Full Text PDFObjectives: Patients with haematologic malignancies (HM) COVID-19 have more severe disease, with increased risk of mortality. Therefore, this study aimed to evaluate the effect of SARS-CoV-2 RNAemia and the specific humoral immune responses on the clinical outcomes of patients with HM and COVID-19.
Methods: Interferon-α/γ (IFN-α/IFN-γ) serum levels, neutralizing antibodies and RNAemia at COVID-19 diagnosis, and persistent RNAemia during the follow-up were evaluated.
Article Synopsis
- A study analyzed myelodysplastic neoplasm (MDS) mortality trends in Spain from 1999 to 2022, focusing on sex and regional differences.
- The research revealed varying MDS mortality rates among men and women across different regions, with significant trends identified: initial decline until 2008, an increase until 2017, and a notable decrease thereafter.
- Key findings included regional variations in mortality trends, with some areas like Andalusia experiencing increases, while others like Aragon saw declines; men consistently faced higher mortality risks than women, underscoring the need for localized healthcare strategies.
Objective: The present study aims to assess the mortality trends in myelodysplastic syndromes (MDS) in Spain from 1980 to 2021.
Methods: Deaths and mid-year population data were collected from the National Institute of Statistics. We estimated age-standardised mortality rates (ASMRs) per 100,000 person-years for all ages and ages 35-64.